The Day In Review: Amgen Drags Biotech Lower

January 26, 2007 – Amgen put a considerable damper on biotech with its 4.5% loss in the Friday session; Genentech will turn its research attention from cancer to immunology; Oscient completed enrollment in a post-approval trial of Factive, its fluoroquinolone antibiotic; Crucell reported its West Nile vaccine passed a Phase I trial; GenVec dosed the first patient in a Phase I/II trial of TNFerade for head and neck cancer; BioVeris has an exclusive license from Baxter for a vaccine that prevents meningitis, sepsis and pneumonia; Pfizer will appeal a decision by a Canadian court that refused to block a generic version of Lipitor; and Enzon received approval of its IND for a new cancer drug. The Centient Biotech 200™ fell 42 points to 4023, a loss of 1.06%. More details...